Business
Bionano Announces Presentation of Optical Genome Mapping Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2024 Annual Meeting
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- A sponsored exhibitor session will feature Dr. Phillip Michaels from Harvard Medical School and Brigham and
About this update from Bionano Genomics, Inc.
[{"type":"text","content":"SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- A sponsored exhibitor session will feature Dr. Phillip Michaels from Harvard Medical School and Brigham and Women’s Hospital presenting data from a multi-site study evaluating the performance and benefits of optical genome mapping (OGM) in comparison to classical methods for hematological malignanciesTwo scientific poster presentations from researchers at Vancouver General Hospital and Dartmouth Hitchcock Medical Center will illustrate the application of Bionano’s OGM workflow in blood cancer researchThree scientific posters featuring results from OGM applications in cancer will be on display at the conference SAN DIEGO, August 1, 2024 (GLOBE NEWSWIRE) – Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the Cancer Genomics Consortium (CGC) 2024 Annual Meeting with a broad range of content covering the utility of optical genome mapping (OGM) for hematological malignancy cancer research, including scientific poster presentations and an exhibitor session featuring data from a multi-site study evaluating OGM’s utility for evaluating hematological malignancies. CGC’s annual meeting brings together industry, medical, and academic professionals to discuss advances in clinical genomics for oncology research. CGC conference sessions will be held August 4-7, 2024, online and in-person in St. Louis, Missouri. As part of a sponsored session, Dr. Phillip Michaels from Harvard Medical School and Brigham and Women’s Hospital will discuss a multi-site, multi-operator study comparing OGM to classical cytogenetic methods for the analysis, interpretation and reporting of clinically relevant variants in hematological malignancies. Dr. Michaels will present the initial study results that assessed consistency across sites, turnaround time, cost effectiveness, concordance with standard methods, and increased yield. The presentation will take place Monday, August 5, from 3:45-4:00 PM CDT in the General Ballroom at the conference. Two scientific presentations highlighting OGM as a novel technique in blood cancer research applications will be given by researchers from Vancouver General Hospital and Dartmouth Hitchcock Medical Center. In addition, three posters featuring results from OGM applications in hematological malignancies and solid tumor research will be on display at the confer...